Alvotech (ALVO)
ALVO trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 20-F (ifrs-full:RevenueFromContractsWithCustomers), period ending 2025-12-31, https://www.sec.gov/Archives/edgar/data/1898416/000189841626000004/0001898416-26-000004-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), period ending 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ALVO on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | Luxembourg |
| IPO year | Not reported by the screener |
| SEC CIK | 0001898416 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | N4 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $586.3M |
| Net income | $27.9M |
| Operating income | Not in SEC XBRL data |
| Net margin | 4.8% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | 75.2× |
| P/S (computed) | 3.6× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-06-16 |
| Latest annual report | 20-F | 2026-03-31 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-10-14 |
Source: SEC EDGAR submissions feed, 301 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -11.1% |
| 1 month | +3.6% |
| 3 months | +54.3% |
| Year to date | +1.4% |
| 1 year | -34.8% |
| From 52-week high | -42.1% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NVAX | Novavax Inc. | $12.82 | +1.26% | $2.1B |
| VCEL | Vericel Corporation | $40.30 | -0.79% | $2.1B |
| BCRX | BioCryst Pharmaceuticals Inc. | $8.07 | -3.47% | $2.1B |
| RXRX | Recursion Pharmaceuticals Inc. | $3.83 | -4.36% | $2.1B |
| ADMA | ADMA Biologics Inc | $10.31 | +1.28% | $2.3B |
| MESO | Mesoblast Limited | $13.89 | -2.63% | $1.8B |
| VIR | Vir Biotechnology Inc. | $10.61 | -6.11% | $1.8B |
| BEAM | Beam Therapeutics Inc. | $24.43 | -2.79% | $2.5B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier